ImmunoGen Reports Recent Progress and 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Immunogen (IMGN) Tops Q4 EPS by 26c, Offers Q1 Guidance
February 12, 2021 6:32 AM ESTImmunogen (NASDAQ: IMGN) reported Q4 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $85.8 million versus the consensus estimate of $37.09 million.
GUIDANCE:
Immunogen sees Q1 2021 revenue of $65-75 million, versus the consensus of $53.1... More
